Core Viewpoint - The announcement highlights the acceptance of the key Phase II registration clinical trial results for TY-9591, a novel EGFR-TKI, at the 2025 World Lung Cancer Conference, indicating significant progress in the treatment of EGFR mutation-positive NSCLC with brain metastases [1] Company Summary - Company has developed TY-9591, a new generation EGFR-TKI, aimed at treating EGFR mutation-positive non-small cell lung cancer (NSCLC) [1] - The clinical trial results will be presented by Professor Shi Yuankai from the Beijing Cancer Hospital, showcasing the drug's efficacy in controlling brain metastases and alleviating symptoms [1] - Company acknowledges uncertainty regarding the successful development, commercialization, and market launch of TY-9591 [1] Industry Summary - The acceptance of the trial results at a prestigious international conference underscores the potential of new treatments in the oncology sector, particularly for challenging cases like NSCLC with brain metastases [1] - The development of targeted therapies like TY-9591 reflects ongoing innovation in the pharmaceutical industry aimed at improving patient outcomes in cancer treatment [1]
同源康医药：艾多替尼在脑转移肺癌患者中展现疗效，将在世界肺癌会议专题汇报